Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
STML After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.08%196.181.2%$557.67m
TSROTESARO, Inc.
0.22%74.2514.4%$534.38m
CELGCelgene Corporation
1.18%69.491.2%$528.88m
GILDGilead Sciences, Inc.
0.34%67.720.9%$508.18m
BIIBBiogen Inc.
0.11%319.791.3%$358.06m
ILMNIllumina, Inc.
1.81%328.903.5%$353.03m
REGNRegeneron Pharmaceuticals, Inc.
-0.50%375.722.6%$262.39m
AAgilent Technologies, Inc.
0.67%71.061.5%$237.22m
VRTXVertex Pharmaceuticals Incorporated
-0.32%173.231.9%$235.67m
ALXNAlexion Pharmaceuticals, Inc.
0.16%114.832.0%$143.36m
SRPTSarepta Therapeutics, Inc.
1.79%125.0015.4%$112.54m
INCYIncyte Corporation
0.28%65.602.5%$104.06m
EXASExact Sciences Corporation
-0.04%69.5225.3%$99.67m
NKTRNektar Therapeutics
-0.63%36.435.5%$97.21m
EXELExelixis, Inc.
-1.78%20.986.4%$82.17m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.